Gene therapy has been hailed as a revolutionary approach to prevent or treat diseases ranging from inherited disorders to cancer. One way to deliver DNA therapy to a patient’s cells is using viruses that do not cause disease in humans. Adeno-associated viruses (AAVs) are the viral carriers of choice for many gene therapy applications due to their history of low immunogenicity and good clinical outcomes for patients.

AAV are produced commercially in mammalian and insect cells, which means scalable, efficient purification strategies are critical to meeting quality standards and clinical demand. Affinity chromatography resins designed to broadly capture AAVs, or capture AAV subtypes, provide solutions to help manufacturers overcome purification bottlenecks. Affinity resins that capture non-target viruses can also clear contaminants to ensure AAV products meet clinical purity standards. With efficient processes in place, biomanufacturers can ensure that AAV production does not hinder the pace of gene therapy development.